1. Genetic perspectives on prostate cancer: unveiling the impact on targeted radionuclide therapies.
- Author
-
Shabbir, Hamid, Imran, Muhammad Babar, and Rubab, Nayyar
- Subjects
- *
CASTRATION-resistant prostate cancer , *POLY ADP ribose , *PROSTATE cancer , *RADIOISOTOPES , *DNA repair - Abstract
Prostate cancer (PCa) is the second most common malignancy in males and the leading cause of cancer-related deaths among men. In recent years, novel therapies have emerged for metastatic castration-resistant prostate cancer including immunotherapy, androgen-receptor signaling inhibitors, and radio-nuclide therapies. DNA Damage Repair (DDR) genes are frequently mutated in advance PCa and are useful biomarkers for targeted therapy such as poly ADP ribose polymerase inhibitors. DDR gene defects may affect tissue radio-sensitivity and could serve as biomarkers for therapy with alpha and beta-emitting radionuclides. Preliminary clinical reports suggest a potential trend toward longer survival in DDR+ subjects when treated with a-emitters, however, survival benefit was not significant in patients treated with β-emitting radionuclides. A comprehensive study regarding the impact of DDR genes in PCa patients treated with alpha emitters is vital. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF